Home Newsfeeds ‘Booker Says There’s Republican Support For ‘SAFE Banking Plus’ Marijuana Compromise’ -Marijuana Moment Report

‘Booker Says There’s Republican Support For ‘SAFE Banking Plus’ Marijuana Compromise’ -Marijuana Moment Report

https://www.marijuanamoment.net/booker-says-theres-republican-support-for-safe-banking-plus-marijuana-compromise/

byBenzinga Newsdesk

August 4, 2022

1 minute read

Booker Says There’s Republican Support For ‘SAFE Banking Plus’ Marijuana Compromise

GH Research’s Psychedelic Drug Candidate For Depression Meets FDA: Clinical Program On Hold

By Lara Goldstein

October 2, 5:56 PM

After the usual 30-day review period, the Food and Drug Administration (FDA) placed GH Research’s (NASDAQ: GHRS) Investigational New Drug (IND) application for a Phase 1 clinical trial of proprietary inhalable 5-MeO-DMT compound GH001 on clinical hold due to “insufficient information to assess risks on huma

GHRS

Ikena Oncology Discontinues IK-930 Program And Cuts Workforce, Analyst Calls It ‘Disappointing’

By Vandana Singh

May 29, 3:33 PM

Ikena Oncology halts its IK-930 program after reviewing clinical data and resources, focusing on the novel MEK-RAF molecular glue, IK-595.

IKNA

Cryptocurrency VeChain Down More Than 3% Within 24 hours

By Benzinga Insights

August 17, 2:04 PM

VeChain's (CRYPTO: VET) price has decreased 3.68% over the past 24 hours to $0.03, continuing its downward trend over the past week of -9.0%, moving from $0.03 to its current price.

VET

Reported Late Thursday, UroGen Announces New Data From The OLYMPUS Trial that Shows Median Durability Of Response Of 28.9 Months For JELMYTO, A Non-Surgical, Chemoablative Treatment For Adults With Low-Grade Upper Tract Urothelial Cancer

By Benzinga Newsdesk

December 2, 2:01 AM

--Results from this ongoing, non-interventional, rollover study were presented at the 23rd Annual Society of Urologic Oncology (SUO) Meeting in San Diego UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company

URGN

‘Booker Says There’s Republican Support For ‘SAFE Banking Plus’ Marijuana Compromise’ -Marijuana Moment Report

Related Posts

GH Research’s Psychedelic Drug Candidate For Depression Meets FDA: Clinical Program On Hold

Ikena Oncology Discontinues IK-930 Program And Cuts Workforce, Analyst Calls It ‘Disappointing’

Cryptocurrency VeChain Down More Than 3% Within 24 hours

Reported Late Thursday, UroGen Announces New Data From The OLYMPUS Trial that Shows Median Durability Of Response Of 28.9 Months For JELMYTO, A Non-Surgical, Chemoablative Treatment For Adults With Low-Grade Upper Tract Urothelial Cancer